DoD Spinal Cord Injury Clinical Trial Award | W81XWH 18 SCIRP CTA

Opportunity Information: Apply for W81XWH 18 SCIRP CTA

The Department of Defense Spinal Cord Injury Research Program (SCIRP) Clinical Trial Award (CTA) is a research funding opportunity intended to speed up the launch and execution of clinical trials that could materially change how spinal cord injury (SCI) is treated or managed. The core idea is to move beyond purely preclinical or exploratory work and put credible, patient-oriented interventions into clinical testing on a timeline that supports real-world impact. The program is structured to back trials that are ready to be implemented and that have a clear path toward improving outcomes for people living with SCI.

Projects under this award can cover a wide range of clinical trial designs and stages. On the early end, the opportunity explicitly allows small proof-of-concept efforts such as pilot studies, first-in-human testing, and Phase 0 trials, where the goal is to demonstrate feasibility, gather preliminary safety or biological activity signals, and generate the kind of data needed to design a larger, more definitive study. On the later end, the program also supports larger-scale trials that aim to determine efficacy in relevant patient populations, meaning studies intended to answer whether an intervention truly works and how well it works for the SCI community being studied. This flexibility makes it suitable both for teams trying to translate a strong therapeutic concept into initial human testing and for groups prepared to run more advanced trials that can influence clinical practice.

The types of interventions the DoD is willing to support are broad, reflecting the varied needs in SCI care. Trials may evaluate new products and medical technologies, pharmacologic agents including drugs and biologics, and medical devices. The scope also extends to clinical guidance and emerging approaches, which can include novel protocols, innovative rehabilitation strategies, and other technology-enabled or procedure-based methods aimed at improving function, reducing complications, or enhancing quality of life. The unifying requirement is that the proposed clinical trial should be positioned to make a meaningful difference in treatment or management, rather than incremental or purely descriptive clinical research.

Administratively, this opportunity was issued by the Department of Defense, Department of the Army, through the U.S. Army Medical Research Acquisition Activity (USAMRAA). The funding opportunity title is "DoD Spinal Cord Injury Clinical Trial Award" and the opportunity number is W81XWH 18 SCIRP CTA. It is listed as a discretionary program, and it can be awarded as either a grant or a cooperative agreement, which typically indicates that some projects may involve more active federal involvement or coordination depending on the award mechanism and project needs. The activity category falls under Science and Technology and other Research and Development, and it is associated with CFDA number 12.420.

Eligibility is described as unrestricted, meaning it is open to any type of entity as long as it meets any additional eligibility conditions that may be specified in the full announcement text. In practical terms, this kind of eligibility language generally allows participation by universities, hospitals, research institutes, nonprofits, for-profits, and other organizations capable of conducting regulated clinical research, including multi-site trials when necessary. The anticipated number of awards is three. The posting information shows a creation date of May 29, 2018, and an original closing date of October 15, 2018. The award ceiling is listed as 0, which usually indicates that a specific maximum dollar amount was not provided in this summary record and would need to be confirmed in the full funding announcement or accompanying program guidance.

Overall, the SCIRP Clinical Trial Award is aimed at accelerating the clinical testing of promising SCI interventions across a spectrum of trial phases, with an emphasis on rapid implementation and high potential impact. It is designed for applicants who can credibly execute a clinical trial and who can justify that their intervention, whether a drug, biologic, device, product, clinical guidance, or emerging technology, could significantly improve the way spinal cord injury is treated or managed in real patient settings.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Spinal Cord Injury Clinical Trial Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on May 29, 2018.
• Applicants must submit their applications by Oct 15, 2018. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 3 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 18 SCIRP CTA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: